Glycine News and Research

RSS

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.

16 Dec 2009

Lunasin may have important health benefits, two new studies report

Two new University of Illinois studies report that lunasin, a soy peptide often discarded in the waste streams of soy-processing plants, may have important health benefits that include fighting leukemia and blocking the inflammation that accompanies such chronic health conditions as diabetes, heart disease, and stroke.

3 Dec 2009

Comprehensive investigation employing FRET to study amino acid transporter GAT1 reported

In the December 2009 issue of the Journal of General Physiology (www.jgp.org), Moss et al. report a comprehensive investigation employing F-rster resonance energy transfer (FRET) to study the {gamma}-amino acid (GABA) transporter GAT1, a member of the family that includes transporters for neurotransmitters dopamine (DAT), serotonin (SERT), norepinephrine (NET) and glycine (GlyT).

1 Dec 2009

The Center for Modeling Optimal Outcomes discovers causal path of autism

During its research into the application of neuroscience in business, a New Jersey based think tank, The Center for Modeling Optimal Outcomes®, LLC (The Center) made an inadvertent and amazing discovery.

18 Nov 2009

Flaw in bone's material leads to disease

The weak tendons and fragile bones characteristic of osteogenesis imperfecta, or brittle bone disease, stem from a genetic mutation that causes the incorrect substitution of a single amino acid in the chain of thousands of amino acids making up a collagen molecule, the basic building block of bone and tendon.

4 Aug 2009

Novel approach for treating cognitive impairments

Researchers have been seeking a safe and effective way to treat cognitive impairments associated with schizophrenia by enhancing N-methyl-D-aspartate (NMDA) glutamate receptors. Functional deficits in NMDA receptors may contribute to the underlying neurobiology of this disorder.

9 Jun 2009

A comparative analysis of four beta blocker trials

ARCA biopharma, Inc. has announced that a comparative analysis of primary endpoint data from four beta blocker trials was presented at the American College of Cardiology 58th Annual Scientific Session being held March 29-31, 2009.

29 Mar 2009

New approach to prostate cancer detection - Sarcosine may distinguish between slow-growing and aggressive prostate cancers

On Friday 20 March, US researcher Dr. Chris Beecher from the University of Michigan gave a well attended lecture about sarcosine, an N-methyl derivative of the amino acid glycine, at the 24th Annual EAU Congress in Stockholm, Sweden.

25 Mar 2009

Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment

Metabolites are molecular fingerprints of what your cells are up to and Dr. Arun Sreekumar wants to know the impression made by cancer.

23 Mar 2009

Researchers discover mechanism that plays a role in the natural production of vitamin C

Researchers from Wageningen University, along with colleagues from the University of Groningen and the University of Pavia (Italy), have unravelled the mechanism that plays a role in the natural production of vitamin C.

17 Feb 2009

Discovery of mechanism that may explain Parkinson's and other neurological disorders

Studying just eight families worldwide, the international team of researchers have discovered a genetic defect that results in profound depression and parkinsonism in a disorder known as Perry syndrome.

12 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

Dual-mode nanoparticles image tumors using MRI and PET

Medical imaging represents one of the most used and useful procedures in the oncologist's diagnostic toolkit, even though each of the most useful techniques-magnetic resonance imaging (MRI), computerized tomography x-ray imaging (CT), and positron emission tomography (PET) scanning-has its own set of limitations.

17 Aug 2008

Glycine could be key to REM Sleep Behavior Disorder

There is new promise on the horizon for those who suffer from REM Sleep Behaviour Disorder (RBD) according to researchers at the University of Toronto.

31 Mar 2008

Neurons use chemical 'chords' to shape signaling

Researchers have discovered that neurons can use two different neurotransmitters that target the same receptor on a receiving neuron to shape the transmission of a nerve impulse.

28 Feb 2008

Blood-vessel blocker aids cancer-killing virus

Cancer-killing viruses are a promising therapy for incurable brain tumors, but their effectiveness has been limited in part because immune cells rapidly move in and eliminate them.

27 Nov 2007

Chocoholics ....blame it on bacteria!

The craving chocoholics have for chocolate is according to new research the result of metabolic programming.

16 Oct 2007

Glycine prevents arthrosis and osteoporosis

Glycine is a non-essential amino acid used by the organism to synthesise proteins and is present in foods such as fish, meat or dairy products.

6 Aug 2007

Gene therapy provides hope for peripheral neuropathy

Researchers from the University of Pittsburgh School of Medicine report that they have successfully used gene therapy to block the pain response in an animal model of neuropathic pain, a type of chronic pain in people for which there are few effective treatments.

1 Jun 2007

In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice

In the first experiment of its kind, investigators at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (CCNE-TR), based at Stanford University, have shown that single-walled carbon nanotubes (SWCNTs) wrapped in poly(ethylene glycol), or PEG, can successfully target tumors in living animals.

8 Jan 2007